Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17922929 | 0.76 | HSD17B10 (0.42) | SMN1; SMN2NPC1HSD17B10ALDH1A1TSHR | |
| SCHEMBL17922894 | 0.76 | HSD17B10 (0.42) | SMN1; SMN2NPC1HSD17B10ALDH1A1TSHR | |
| SCHEMBL17922893 | 0.76 | HSD17B10 (0.42) | SMN1; SMN2NPC1HSD17B10ALDH1A1TSHR | |
| SCHEMBL21408159 | 0.72 | HSD17B10 (0.42) | SMN1; SMN2NPC1HSD17B10ALDH1A1EPHX1 | |
| SCHEMBL24845877 | 0.71 | HSD17B10 (0.39) | SMN1; SMN2NPC1HSD17B10KDM1AALDH1A1 | |
| SCHEMBL27172955 | 0.71 | HSD17B10 (0.39) | SMN1; SMN2NPC1HSD17B10KDM1AALDH1A1 | |
| SCHEMBL24845879 | 0.70 | HSD17B10 (0.39) | SMN1; SMN2NPC1HSD17B10EPHX1LMNA | |
| SCHEMBL16148112 | 0.69 | HSD17B10 (0.42) | SMN1; SMN2NPC1HSD17B10ALDH1A1HPGD | |
| SCHEMBL16031037 | 0.69 | HSD17B10 (0.42) | SMN1; SMN2NPC1HSD17B10ALDH1A1HPGD | |
| SCHEMBL16031035 | 0.69 | HSD17B10 (0.39) | SMN1; SMN2NPC1HSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2023-09-14 | — | — | US | disclosed |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | GABRA5, GABRA1, P2RX5 | SMN1; SMN2 2384/4885NPC1 1595/4885HSD17B10 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.